jack moss

1

The rise of subcutaneous biologics has transformed the pharmaceutical landscape. Patients and providers alike now prefer injectable therapies that reduce hospital visits, dosing frequency, and complexity. But behind the scenes, formulation scientists face a critical challenge: how to manage biologic viscosity in high-concentration injectable proteins. Whether you’re working on monoclonal antibodies or GLP-1 analogs, the push for higher protein concentrations—sometimes exceeding 200 mg/mL—comes with steep viscosity trade-offs that can affect delivery, manufacturability, and patient experience.

Experience

• Joined APSense.com

  Oct 2025